Blogs
If an analyte is amenable to analysis, it’s difficult to ignore the benefits that LC-MS/MS can provide. There are numerous challenges associated with using LC-MS/MS for the bioanalysis of oligonucleotides that have slowed its utilization for these assays. These include: However, the increased adoption of LC-MS/MS for oligonucleotides…
December 10
- December 11
KCAS Bio at BioFIT 2026 KCAS Bio will be attending BioFIT on December 10th–11th in Marseille, France. As Europe’s leading partnering event for technology transfer, academia-industry collaboration, and early-stage innovation deals in life sciences, BioFIT brings together big pharma, emerging biotech, investors, and research institutions for one-on-one meetings, conferences,…
Posters & Papers
KCAS Bio collaborated with Phenomenex to demonstrate how magnetic bead-enabled hybrid LC-MS workflows are advancing modern bioanalysis for increasingly complex biotherapeutics. The case study explores how magnetic bead-based affinity capture enhances selectivity, sensitivity, and multiplexing, enabling more reliable quantitation of modalities such as monoclonal antibodies, ADCs,…
August 22
- August 28
KCAS Bio at the 26th International Mass Spectrometry Conference (IMSC 2026) KCAS Bio is excited to attend the 26th International Mass Spectrometry Conference (IMSC 2026), taking place August 22–28, 2026, in Lyon, France. As one of the world’s premier events for mass spectrometry, IMSC brings together…
Blogs
Background on the cancer vaccine program A clinical-stage biotech company approached KCAS Bio to support their oncology immunotherapy program, a first-in-class cancer vaccine leveraging pathogen-derived peptide sequences sharing high homology with disease-associated protein variants expressed in cancer cells. The sponsor wanted to monitor and characterize vaccine-specific immune responses, evaluate…
Blogs
Over the past decade, drug conjugates have emerged as one of the most important innovations in pharmaceutical development. Rather than relying on a drug molecule to find its target on its own, conjugation technologies allow scientists to attach therapeutic payloads to carriers that improve delivery, targeting, stability, and efficacy.
June 30
- June 30
KCAS Bio is excited to announce our participation in the Healthtech Accelerations Summit (HAS) 2026, taking place on June 30 in Paris, France. This prestigious event brings together global leaders in biotechnology, pharmaceuticals, and digital health to discuss the latest breakthroughs, investment opportunities, and regulatory advancements shaping the future…
November 15
- November 18
KCAS Bio will be attending the ACT Annual Meeting on November 15th – 18th in San Antonio, Texas. The ACT Meeting gathers the toxicology community for four days of scientific exchange, networking, and professional development. With a strong focus on applied toxicology, the meeting features a robust scientific…
November 4
- November 8
KCAS Bio will be attending SITC on November 4th – 8th in Phoenix, AZ. SITC convenes researchers, clinicians, and biopharmaceutical developers to explore the latest breakthroughs in immune-based cancer treatments. These field experts will discuss cutting-edge research and clinical needs within immuno-oncology, such as new checkpoint inhibitors, cancer…
October 25
- October 28
KCAS Bio will be exhibiting at AAPS PharmSci 360 on October 25th – 28th in New Orleans, LA. Pharmaceutical Sciences at KCAS Bio AAPS PharmSci 360 brings together pharmaceutical scientists and industry leaders to explore advances across the drug development lifecycle, from discovery and preclinical research through…
October 19
- October 22
KCAS Bio will be exhibiting at the Immunogenicity & Bioassay Summit on October 19th-22nd in Alexandria, VA. Stop by and visit us at Booth #9. This annual summit, hosted by the Cambridge Healthtech Institute, brings together leaders in immunogenicity assessment, bioassay development, and translational science to explore emerging…
webinars
This talk explores the expanding role of flow cytometry in CAR-T and cellular therapy bioanalysis—from its origins supporting the earliest autologous CAR-T clinical trials to its expanding role in next-generation in vivo CAR therapies. We will trace how flow cytometry methods have matured alongside the CAR landscape, becoming a primary platform…